These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2629244)

  • 21. L-arginine and polyamine administration protect beta-cells against alloxan diabetogenic effect in Sprague-Dawley rats.
    Méndez JD; Hernández Rde H
    Biomed Pharmacother; 2005 Jul; 59(6):283-9. PubMed ID: 15996850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Diabetogenic action of alloxan in short-term termination of the blood supply to the pancreas and spleen].
    Ul'ianov AM; Tarasov IuA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1984; (8):48-51. PubMed ID: 6487685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [C-peptide, diabetogenic factor and the blood anticoagulating system in patients with the insulin-dependent type of diabetes mellitus before and after heparin therapy].
    Balabolkin MI; Kudriashov BA; Levitskaia ZI; Liapina LA; Ul'ianov AM
    Probl Endokrinol (Mosk); 1990; 36(1):25-8. PubMed ID: 2330356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experimental stimulation by protamine sulfate of the hyperglycemic action of the diabetogenic factor].
    Kudriashov BA; Pytel' IuA; Ul'ianov AM; Tarasov IuA
    Biull Eksp Biol Med; 1986 Jul; 102(7):16-8. PubMed ID: 3730582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Heparin clearance during activation of the anticoagulation system in animals].
    Ul'ianov AM
    Biull Eksp Biol Med; 1978 Jun; 85(6):651-4. PubMed ID: 667338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prophylactic effect of vitamin A, neutralizing the development of experimental insulin-dependent diabetes in animals].
    Kudriashov BA; Ul'ianov AM; Tarasov IuA
    Vopr Med Khim; 1993; 39(1):20-2. PubMed ID: 8498064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Physicochemical properties of the diabetogenic factor and its complex with heparin].
    Kudriashov BA; Ammosova IaM; Liapina LA; Ul'ianov AM
    Farmakol Toksikol; 1987; 50(3):49-52. PubMed ID: 3609278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Isolation and various physico-chemical properties of diabetogenic factor from the blood of patients with diabetes].
    Kudriashov BA; Liapina LA; Azieva LD
    Vopr Med Khim; 1989; 35(6):63-6. PubMed ID: 2629241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against alloxan diabetes by low-dose 60Co gamma irradiation before alloxan administration.
    Takehara Y; Yamaoka K; Hiraki Y; Yoshioka T; Utsumi K
    Physiol Chem Phys Med NMR; 1995; 27(3):149-59. PubMed ID: 8868575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of the antithrombin III-heparin-thrombin complex in the defense reaction of the anticoagulation system].
    Kudriashov BA; Liapina LA; Pastorova VE
    Vopr Med Khim; 1988; 34(2):38-42. PubMed ID: 3400189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Changes in the diabetogenic factor activity in the blood plasma of children with diabetes mellitus resulting from systematic heparin administration].
    Kudriashov BA; Zhukovskiĭ MA; Shcherbacheva LN; Ul'ianov AM; Bazaz'ian GG
    Pediatriia; 1985 Aug; (8):46-7. PubMed ID: 4069883
    [No Abstract]   [Full Text] [Related]  

  • 32. [The toxic action of the "diabetogenic factor" metabolite in the body during the development of insulin-dependent diabetes].
    Kudriashov BA
    Izv Akad Nauk Ser Biol; 1993; (5):694-702. PubMed ID: 8220079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Animal sensitivity to the diabetogenic action of alloxan during cold adaptation].
    Shorin IuP; Seliatitskaia VG; Nepomniashchikh GI; Pal'chikova NA; Khodova RR
    Biull Eksp Biol Med; 1984 Aug; 98(8):240-2. PubMed ID: 6466864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Insulin-heparin complex, its physiological properties].
    Kudriashov BA; Pytel' IuA; Liapina LA; Baskakova GM
    Vopr Med Khim; 1981; 27(4):547-52. PubMed ID: 7027617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Age-related characteristics of the manifestation of the diabetogenic factor in the blood of animals maintained on natural and atherogenic diets].
    Kudriashov BA; Ul'ianov AM; Bazaz'ian GG; Pytel' IuA
    Probl Endokrinol (Mosk); 1984; 30(2):65-70. PubMed ID: 6718336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in the diabetogenic effect of alloxan in mice by treatment with the antineoplastic agent ICRF-187.
    El-Hage AN; Herman EH; Ferrans VJ
    Res Commun Chem Pathol Pharmacol; 1981 Sep; 33(3):509-23. PubMed ID: 7036302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antidiabetic properties of high molecular weight heparin-adenosine triphosphate complex].
    Ul'ianov AM; Liapin LA; Pastorova VE
    Izv Akad Nauk Ser Biol; 2006; (1):77-80. PubMed ID: 16521542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of thymic peptides on the development of streptozotocin-induced diabetes mellitus].
    Novikov VI; Molotkov OV; Podcheko AP; Babichev AV
    Patol Fiziol Eksp Ter; 1999; (3):25-8. PubMed ID: 10498991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antianemic effect of reamberin in rats with acute alloxan-induced diabetes].
    Volchegorskiĭ IA; Tishevskaia NV; Dement'eva EV
    Eksp Klin Farmakol; 2008; 71(6):23-7. PubMed ID: 19140511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Nature of the diabetogenic factor of blood plasma in clinical and experimental diabetes].
    Kudriashov BA; Liapina LA; Ul'ianov AM
    Probl Endokrinol (Mosk); 1985; 31(6):51-3. PubMed ID: 4088993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.